EZH2 Activating Mutation

CI-VAR-00000182Explore in graph →CIViC 3737

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Follicular Lymphoma2
EZH2 Activating Mutation	Tazemetostat	Predictive	A	Supports Sensitivity Response	3	accepted	EID9709 Tazemetostat was found to have increased anti-tumor activity in patients with relapsed/refractory follicular lymphoma with gain-of-function EZH2 mutations (cobas EZH2 Mutation Test; objective response… (full text at CIViC) PMID 33035457 · Morschhauser et al., 2020 · Open in CIViC	civic
EZH2 Activating Mutation	Tazemetostat	Predictive	C	Supports Sensitivity Response	1	accepted	EID11107 In this phase I study, four Japanese patients with follicular lymphoma were recruited to test the efficacy of EZH2 inhibitor-Tazemetostat. Patients were screened for presence of EZH2 mutations and onl… (full text at CIViC) PMID 33492746 · Munakata et al., 2021 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.